Can a drug like Ozempic help treat addictions to alcohol, opioids or other substances? 
The hidden racist history of hair loss 
‘They don’t have enough’ – schools in England are running food banks for families 
New Study Reveals Coke, Pepsi, and Nestle as Top Plastic Polluters 
Hertz to Offload 30K EVs This Year, Deepens Cuts Amid Mounting Fleet Losses 
PUMA and Scuderia Ferrari HP Unveil Miami Limited Edition Collection 
Impact of Iran-Israel conflict on Stocks, Gold and Bitcoin 
Industry shutdowns are messy and painful: 4 lessons Australia’s coal sector can learn from car-makers about bowing out 
Eye infections might seem like a minor complaint – but in some cases they can cause blindness and even death 
Inflation is slowly falling, while student debt is climbing: 6 graphs that explain today’s CPI 
Extraordinary Vietnam fraud case exposes the inherent vulnerabilities of banks 
Binance Reassures Filipino Users Amid SEC App Removal Request, Urges Balanced Review by Google and Apple 
The yen plunges to 34-year low despite interest rate hike 
UK smoking ban would have many benefits for public health – but only if it’s effectively implemented 
Study links microplastics with human health problems – but there’s still a lot we don’t know 
Samsung Biologics, South Korea's biotech behemoth, expands its portfolio in a $1.08 billion deal with U.S. pharma titan, Pfizer, marking a landmark in global biotech manufacturing. The enhanced partnership will leverage Samsung's newest facility to produce Pfizer's multiproduct biosimilar portfolio.
This includes a new contract signed with Pfizer, building upon the initial deal established in March. Under the new agreement, Samsung Biologics will manufacture an additional $193 million of Pfizer products.
Additionally, Samsung Biologics will produce Pfizer's multiproduct biosimilar portfolio, encompassing oncology, inflammation, and immunotherapy, with a value of $704 million. The company will extend its manufacturing capabilities to provide Pfizer ample capacity for large-scale production of a multiproduct biosimilar portfolio.
This strategic collaboration will occur at Samsung Biologics' newest facility, Plant 4, in Songdo, South Korea. Completing the 240,000-liter biomanufacturing plant in June 2023 marks a significant milestone in the continued growth of Samsung Biologics.
Mike McDermott, Chief Global Supply Officer and Executive Vice President at Pfizer, expressed his enthusiasm for the partnership, stating they are pleased to extend the strategic collaboration with Pfizer as we share and support their strong vision to bring innovative solutions for patients around the globe.
These manufacturing partnerships solidify Samsung Biologics' position in the global contract development and manufacturing organization (CDMO) market. As part of its expansion strategy, the company is increasing its production capacity and aims to become a major player in the industry.
The contracts with Pfizer highlight the long-term strategic partnership between the two companies, further establishing Samsung Biologics as a trusted collaborator. The company plans to explore new avenues in overseas markets by considering opening new sales offices to facilitate communication with global customers. With an existing office in New Jersey and a research and development center in San Francisco, Samsung Biologics is set for continued growth on a global scale.
